Printer Friendly

Printed from http://www.researchandmarkets.com/reports/338507

Molecular Diagnostics - Global Strategic Business Report

Description:
This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousands by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 165 companies including many key and niche players such as:

- Abbott Laboratories
- Becton, Dickinson and Company
- bioMérieux SA
- Cepheid
- CytoCore Inc.
 
Contents:
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOK

Molecular Diagnostics
A Prelude
Current and Future Analysis
US and Europe
Leaders in Molecular Diagnostics Adoption
Developing Countries Excel in Growth Prospects
Major Growth Drivers
Key Market Trends in a Nutshell
Major Technology Trends
Major Issues and Challenges
The Future in Store

2. MEDICAL DIAGNOSTICS MARKET A REVIEW

Clinical Diagnostics Industry
Trends and Tendencies
Global In-Vitro Diagnostics (IVD) Market: A Prelude
Table 1: Global In Vitro Diagnostics Market by Leading Players (2013): Percentage Share Breakdown of Revenues for Abbott Laboratories, bioMérieux, Danaher, J&J, Roche Diagnostics, Siemens and Others (includes corresponding Graph/Chart)
Table 2: Global In-Vitro Diagnostics Market by Segment (2013): Percentage Breakdown of Value Sales for Hematology, Hemostasis, Immunochemistry, Microbiology, Molecular Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood Glucose, and Tissue Diagnostics (includes corresponding Graph/Chart)
Table 3: Global In-Vitro Diagnostics Market by Sector (2013): Percentage Breakdown of Revenues for Decentralized & Patient Self-Testing and Hospital & Commercial Laboratories (includes corresponding Graph/Chart)
Classification of Diagnostic Tests
Molecular Diagnostics
A Replacement and Enabling Technology
Advancements in Molecular Diagnostics
A Boon for the Industry
Nucleic Acid Diagnostics Market
An Overview

3. MOLECULAR DIAGNOSTICS INDUSTRY AN OVERVIEW

Molecular Diagnostics
A Rapidly Advancing Market
Molecular Diagnostics: Marking the Convergence of Numerous Technologies
Towards Tailoring the Right Treatment for the Right Disease
Business Opportunities in the Offing
Improving Healthcare Expenditure Turbo Charges Demand
Table 4: Per-Capita Healthcare Expenditure in Select Regions (2013) (includes corresponding Graph/Chart)
Table 5: Top 20 Countries with the Highest Healthcare Spending as a Percentage of GDP (2012) (includes corresponding Graph/Chart)
Table 6: Top 10 Countries with Highest Private Spending on Health Care (2011) (includes corresponding Graph/Chart)
Demographics Spell Growth Opportunities
Table 7: Global Population Statistics for the 65+ Age Group (2013) (includes corresponding Graph/Chart)
Table 8: Elderly Population (60+ Years) as a Percentage of the Total Population (2012 & 2050) (includes corresponding Graph/Chart)
Table 9: Global Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
Table 10: Aging Population by Age Group in More Developed Countries (1975-2050) (includes corresponding Graph/Chart)
Table 11: Aging Population by Age Group in Less Developed Countries (1975-2050) (includes corresponding Graph/Chart)
Table 12: Aging Population by Age Group in Least Developed Countries (1975-2050) (includes corresponding Graph/Chart)
Table 13: Life Expectancy at Age 60 and 80 Years
(2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
Technological Innovations Set to Drive the Market
The Role of Molecular Diagnostics in Personalized Medicine
Companion Diagnostics Make Way for Personalized Medicine
List of Select FDA-Cleared Companion Diagnostic Devices
Biomarkers as Companion Diagnostics
Proteomics Technologies: Growing in Significance
New Developments in Proteomics Technologies
New Applications Hold Promising Potential
Molecular Diagnostics for Lymphoid Malignancies
Next-Generation Sequencing Technologies Keep Up the Momentum
Select Commercial NGS Technologies
Select Promising NGS Technologies in Development (As of 2012)
Rising Emphasis on Lab Automation to Augur Well for Market Growth
List of Fully Automated and Rapid Molecular Diagnostics
Molecular Diagnostics and Intellectual Property
Medical Training and Practice Challenges
The Enlightened Consumer of the 21st Century
Information Handling & Processing: The Soft Side of Diagnostics
Hurdles All the Way for Companies Eyeing Molecular Diagnostics
Molecular Diagnostics
Moving from Centralization to Decentralization
Migrating to Decentralized Format
Going Ahead with Decentralization
Limited Reimbursements by Third Party Payers
A Stumbling Block

4. AN INSIGHT INTO APPLICATIONS OF MOLECULAR DIAGNOSTICS

Infectious Diseases Molecular Testing
Overview
Activity in the Field
Identifying Multidrug Resistance
Infectious Disease Treatment Monitoring
Other Infectious Diseases Applications
Key Trends
Increasing Incidence of Infectious Diseases Fuel Adoption
Table 14: Reported Cases of Major Infections by Select Geographic Region: 2011
Rising Incidence of Hospital Acquired Infections Propels Market Growth
Comparison of Different Parameters for Select C. diff MDx Tests
Rising HIV Prevalence Provides Ample Growth Opportunities
Table 15: Global Prevalence of HIV Infection in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
Table 16: Newly Infected HIV Population in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
Table 17: Global HIV Related Deaths in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
Table 18: Top Twelve Countries in APAC with The Highest HIV Incidence (2012) (includes corresponding Graph/Chart)
Infectious Disease Testing
A Major Driver of Molecular Diagnostics Market
Select FDA-Cleared Molecular Diagnostic Tests for Infectious Diseases
Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
HPV Testing: A Fast Growing Segment in the Molecular Diagnostic Testing Market
List of Select HPV Molecular Diagnostic Tests by Company and Technique
Archaic TB Diagnostic Methods Opens Up Opportunities for Molecular Diagnostics
List of Select Commercially-Available TB Diagnostics
An Overview of Select TB Diagnostics under Development
Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential
PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
Blood Screening
Molecular based Tests Ingrain Roots in Blood Donor Screening Segment
Cancer Screening & Diagnosis
Overview
Molecular Tests Lead the Way for Cancer IVD Market Growth
Molecular Markers to Enhance Thyroid Cancer Diagnosis
Oncology-Based Molecular Diagnostics: The Propitious Segment
List of US-FDA Approved Biomarkers for Cancer
Table 19: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart)
Table 20: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart)
Table 21: Medical Costs Associated with Cancer by Affected Site: 2010 (includes corresponding Graph/Chart)
Growing Popularity of Chemo-Sensitivity Testing of CTCs
Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers
Other Testing Applications
Genetic Disease Testing Applications
Overview
Pharmacogenomics
Prognosis Based on Genomics
Pharmacogenomics Development Augurs Growth of Genetic Testing Market
Prospects for Genetic Diagnostics and Testing Grow Brighter
List of Select FDA-Cleared Genetic Tests by Disease
Genetic Testing
An Indispensible Tool for Cystic Fibrosis
Table 22: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)
Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions
Non-Invasive Prenatal Diagnostics
The Way Ahead
Nucleic Acid Amplification Methods for Detection of Antimicrobial Resistance
PCR-Based Nucleic Acid Amplification for Detection of Antimicrobial Agents
Histocompatibility Testing
Table 23: Global HLA Testing Market (2012-2016E): Revenue Estimates for 2012 through 2016 (includes corresponding Graph/Chart)

5. COMPETITIVE DYNAMICS IN THE MOLECULAR DIAGNOSTICS MARKET

Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market
An Overview of Competitive Landscape in Molecular Diagnostics
Table 24: Leading Players in the Global Molecular Diagnostics Market (2012): Percentage Share Breakdown by Value Sales for Abbott, Becton, Dickinson & Company, bioMérieux, Cepheid, Hologic/Gen-Probe, Novartis, Qiagen, Roche Diagnostics, Siemens and Others (includes corresponding Graph/Chart)
Other Noteworthy Companies and their Competitive Position by Segment
Key Players and Their Technologies
The Top Tier
Mid-Sized and Small Companies
Cepheid: Unquestioned Leader in the Rapid and Automated MDx Market
Price Comparison of Select Fully Automated and Rapid Molecular Diagnostics
Qiagen: The Leading Player in the Global HPV MDx Market
Comparative Analysis of Select HPV MDx Tests
Competitive Dynamics in the C. difficile Testing Market
Table 25: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2013): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian and Others (includes corresponding Graph/Chart)
List of Select Molecular C. difficile Test Products
Competition in the Blood Screening MDx Market
Table 26: Global Blood Screening MDx Market by Leading Players (2013): Percentage Market Share Breakdown of Value Sales for Hologic Gen-Probe, Roche and Others (includes corresponding Graph/Chart)
Competitive Landscape in the Global RT-PCR Market
Table 27: Leading Players in Global RT-PCR Instruments Market (2012): Percentage Breakdown of Value Sales for Life Sciences Research by Leading Players
Life Technologies, Bio-Rad, Roche, Agilent, Qiagen and Others (includes corresponding Graph/Chart)
Select Real-Time PCR Products by Company
Competition Heats Up in dPCR Market
Table 28: Leading dPCR Systems At a Glance
Life Sciences Companies Eye on Lucrative Prostate Cancer MDx Market
Consolidation Activity Continues to Strengthen Driven by New Entrants
Major M&A Transactions in Molecular Diagnostics: 2011-2014
New Entrants in Molecular Diagnostics Landscape: 2010-2013
Some Examples of Recent Transactions by New Entrants in the MDx Market
Product Marketing
Key to Commercial Success

6. PRODUCT & TECHNOLOGY OVERVIEW

Molecular Diagnostics
Definition & Scope
Molecular Diagnostics
Impact on Healthcare
Utility of Molecular Diagnostic Tests
Background of Molecular Diagnostics
Major Milestones in the Evolution of Molecular Diagnostics
Types of Molecular Diagnostics
Conventional Diagnostics Vs. Molecular Diagnostics
Unabated Developments in Molecular Diagnostics Technology
Signal Amplification Technologies
PCR
New Developments
Quantitative Real-Time PCR for Molecular Diagnostics
Signal Detection and Quantification
Quantitative Real-Time RT-PCR Analysis
Applications of Quantitative Real-Time PCR Analysis
Digital PCR
Non-PCR Methods
Other Signal Amplification Technologies
DNA Probe Based Products
Direct Detection of Specific Nucleic Acid Sequences
Nucleic Acid Amplification and Detection
DNA Sequencing and Gene Detection
Arrays of Immobilized Probes (DNA Chips) in Gene Detection
RNA Diagnostics
Complementary Molecular Diagnostic Technologies
Fluorescent In-Situ Hybridization (FISH)
DNA Biochips/Microarrays
Biosensors
Proteomic Technologies for Molecular Diagnostics
Nanotechnology for Molecular Diagnostics
Technologies on the Anvil
Haplotype Analysis
A Distant Possibility
Chronic Multi-Gene Defects Now Diagnosable
Whole Genome Sequencing
Boon or Bane to Genetic Testing?

7. PRODUCT APPROVALS/INTRODUCTIONS

Grifols Obtains CE-Marking for ID CORE XT Molecular Diagnostic Kit
QIAGEN Rolls Out careHPV™ Test in India
QIAGEN Gets PMA Approval from the US FDA for artus® CMV RGQ MDx Kit
Alere Obtains FDA Approval for Alere™ i Influenza A and B Test
Qiagen Obtains Approval from the US Health Regulators for Gene-Testing Kit
Immucor Obtains the US FDA Approval for PreciseType HEA Test
bioMérieux Obtains PMA Approval from the FDA for THxID™-BRAF Companion Diagnostic Test
Cepheid Obtains FDA Clearance for Xpert® MTB/RIF Test
Roche Gains FDA 510(k) Approval to use Four Additional Specimens with Cobas Ct/Ng V2.0 Test
PrimeraDx Gains FDA 510(k) Clearance for ICEPlex System
Illumina Receives FDA Premarket Approval for Miseqdx System
Hologic Obtains Health Canada Approval for Aptima HPV Assay
Life Technologies Obtains NDIS Approval for GlobalFiler Express Kit
Serascience Obtains CE Mark Approval for Seralite®
IntelligentMDx Obtains US FDA Approval for Automated Molecular Diagnostic Test
Meridian Bioscience Obtains FDA Approval for illumigene® Mycoplasma
IntelligentMDx Obtains CE-Mark Approval for IMDx Flu A/B and RSV Test
BD Diagnostics Obtains FDA Approval for BD MAX™ Cdiff Assay
Quidel Obtains 510(k) Approval for Quidel Molecular RSV + hMPV Assay
Roche Seeks FDA Approval for Cervical Cancer Primary Screening Indication for the Cobas® Hpv Test
Quidel Gets FDA Nod for New Molecular Diagnostic Tests
Abbott Launches RealTime Molecular Test for HPV
Diagnovus Introduces ENGAUGE™-Cancer DLBCL Gene Panel
Roche Introduces Cobas p 480 Instrument
LabCorp Launches BRCAssureSM Breast Cancer Mutation Tests
Cytocell Introduces Cytocell CLL FISH Probes
Cancer Genetics Introduces FHACT™ DNA-Based Cervical Cancer Diagnostic Test
Abbott Releases IMDx C.difficile Test
Myriad Genetics Introduces myPath™ Melanoma Molecular Diagnostic Test
Biocartis Develops New MDx Prototype Platform
BioChain Collaborates with Epigenomics to Introduce Septin9 IVD Test
Advanced Cell Diagnostics and Kindstar Partner to Introduce New Molecular Diagnostic Assays
EKF Diagnostics Introduces Four New PointMan™ DNA Enrichment Kits
DiaCarta Introduces QClamp™ Somatic Mutation Real-Time PCR Tests
Biocartis to Launch Idylla Molecular Diagnostic Platform
Personalis Launches the ACE Clinical Exome™
Roche to Launch Cobas 6800 and Cobas 8800 MOLECULAR Dx Systems
Illumina Launches TruSight One Sequencing Panel
Abbott Laboratories Releases New FDA-Approved Molecular Diagnostic Flu A/B and RSV Test
Natural Molecular Testing Releases New Diagnostic Molecular Tests for Women
DiaSorin’s Molecular Division Launches Iam Toxo Assay for T. gondii Detection
Myriad Genetics Introduces myRisk™ Hereditary Cancer Panel
BD Diagnostics Launches FDA-Cleared BD ProbeTec™ Trichomonas Vaginalis Qx Amplified DNA Assay
ELITechGroup Molecular Diagnostics Introduces ELITe STAR
Assurex Health Launches GeneSight Psychotropic 2.0
Theradiag Rolls Out two new Multiplexed Molecular Diagnostic Assays
Bioline Releases the MyTaq™ Extract-PCR Kit
HTG Rolls Out HTG Edge DMPK Assay and HTG Edge TOA Assay
BD Diagnostics Introduces Real-Time PCR Kit for Diagenode Bordetella Pertussis/Parapertussis Detection
Abbott Launches Real-time HCV Genotype II Test
Abbott Introduces FDA-Approved Real-Time HCV Genotyping Test Assay
DiaSorin Releases New IAM PARVO Molecular Diagnostic Test for Parvo Virus Detection
GeneDx to Introduce Comprehensive Breast Cancer Genetic Tests
Vela Diagnostics Develops New PCR-based Assays Targeting the H7N9 Bird Flu Strain
Cancer Genetics Introduces UroGenRA™ Urogenital Cancer Array
Bioline Releases ISOLATE II Nucleic Acid Purification Kits
MLabs Announces Commercial Availability of MiPS Test for Prostate Cancer
Cancer Genetics Introduces New Genetic Test for Cervical Cancer Management
Knight Diagnostic Laboratories Launches GeneTrails Cancer Tests
Integrated Diagnostics Releases Xpresys™ Lung Blood Test
Seegene Unveils Real-Time Array Technology for POC Testing
Medical Diagnostic Laboratories Releases New Azithromycin Resistance Reflex Assay for Chlamydia Trachomatis
BD Diagnostics Introduces New Molecular Test
Nanosphere Receives FDA Authorization for Marketing BC-GP Test
Abbott Secures CE Marking for PLEX-ID™ System and Clinical Assays

8. RECENT INDUSTRY ACTIVITY

Thermo Fisher Scientific Acquires Life Technologies
Myriad Genetics Takes Over Crescendo Bioscience
AUT University Collaborates with Roche Diagnostics
Corgenix Medical Obtains NIH Grant to Advance Development of Ebola Rapid Diagnostic Test Kit
Cepheid Collaborates with AstraZeneca, Cubist Pharmaceuticals and GSK
B Braun US and CeGaT Join Forces to Establish B Braun CeGaT
Provista Diagnostics Expands Exclusive License Agreement for Certain Biomarker and Autoantibody Technologies
Veracyte and Fleury Partner to Offer the Afirma® Gene Expression Classifier
Integrated Diagnostics Attracts Financing for Xpresys Lung Molecular Diagnostic Blood Test
MDxHealth Enters into Agreement with Galaxy Health
QIAGEN Acquires Exclusive Worldwide License to CALR Biomarker
Zyomyx Obtains $7.5 Million from UNITAID to Launch MyT4™ POC CD4 Test
Human Longevity Inc. Commences its Operations
Roche Takes Over IQuum
Myriad Genetics and Sividon Diagnostics Ink Exclusive Co- Marketing Agreement
Grifols to Acquire Transfusion Diagnostics Unit of NOVARTIS Diagnostics
Life Technologies and Advanced Cell Diagnostics Enter into Global Distribution Agreement
Microbiologics Acquires Phthisis Diagnostics
bioMérieux Enters into Agreement to Acquire BioFire Diagnostics
Response Genetics Takes Over Substantial Assets of Pathwork Diagnostics
Mobidiag, Genewave and Amplidiag Merge
EKF Diagnostics Holdings Established New Subsidiary
Cynvenio and CollabRx Collaborate for Cancer Molecular Diagnostics
bioTheranostics Inks Collaboration Agreement with Mayo Clinic and Mayo Medical Laboratories
bioMérieux Terminates Collaboration with Biocartis in Molecular Biology Field
Rosetta Genomics Expands Distribution Agreement with GeneKor for microRNA Cancer Testing Services
QIAGEN Enters into an Agreement with Eli Lilly
Transgenomic Collaborates with PerkinElmer
Diagnoplex and Unilabs Ink Collaboration Agreement to Commercialize Colox
Pacific Edge Inks Agreement with FedMed
PDI and Transgenomic Sign Long-Term Collaboration Agreement for CardioPredict™ Molecular Diagnostic Test
HiberGene Obtains US Patent Rights for Molecular Diagnostic Test for Meningococcus
OncoDNA Signs Collaboration Agreement with IBBL
MDxHealth Collaborates with HistoGeneX
Co-Diagnostics Partners with DNA Logix to Form Infectious Disease Dx Joint Venture
Lumora and Promega Sign Supply Agreement for Ultra-Glo™ Luciferase
MDxHealth Enters into Partnership with Summit Pharmaceuticals
Myriad Genetic Enters into Agreement with TESARO
Cancer Genetics Enters into Distribution Agreement with Excilone
Cancer Genetics Italia Enters into Agreement with Nikon Instruments
CollabRx and OncoDNA Enter into Long-Agreement to Buy CollabRx SaaS-based Technology and Content Resources
CollabRx Enters into Partnership with Sengenics for Molecular Diagnostics
Diasorin Enters into Agreement with Seegene
Cancer Genetics Appoints Cytogen and Cytogen Polska as Distributors for CGI Italia DNA-FISH Probes
FDA Re-Categorizes Meridian Bioscience’s illumigene® Group A Streptococcus and illumigene® Group B Streptococcus Tests
Kreatech Signs Agreement with LCMC
HiberGene Diagnostics Commences Manufacturing Process for Meningococcus MDx Test
SYGNIS Pharma to Foray into Molecular Diagnostics Products Business
IntelligentMDx Signs Long-Term Agreement with QIAGEN
The Icahn School of Medicine Collaborates with Exosome Diagnostics
Tianjin Cancer Hospital Joins Forces with Tektronix
Maverix Biomics Enters into Co-Marketing Agreement with QIAGEN
CollabRx Enters into Multi-Year Agreement with Quest Diagnostics
Personal Genome Diagnostics Collaborates with MolecularMD
Applied Proteomics Collaborates with the German Cancer Research Center
Diagnoplex and Unilabs Ink Collaboration Agreement
CombiMatrix Enters into Strategic Alliance with Manhattan Labs
MRIGlobal and Evogen Ink Agreement for Molecular Diagnostics Products Development
Rheonix Signs Joint Development Agreement with Life Technologies
Qiagen Collaborates with Exosome Diagnostics
Diaxonhit and XDx Sign Definitive Exclusive License and Distribution Agreement
Genewiz Enters into Partnership with Chinese KeyTest Diagnostics
IncellDx Inks Agreement with GeneCell Diagnostics
PrimeraDx Enters into Agreement with Quest Diagnostics to Co- Develop Companion Diagnostics
Evogen Inks Licensing Agreement with Focus Diagnostics
Lpath Enters into Collaboration and License Agreement with Provista
Lab21 Inks Agreement with IntegraGen
Analytik Jena Acquires SIRS-Lab
Swift Biosciences Enters into Licensing Agreement with Vela Operations
BioFire Secures $25 Million Fund from Athyrium

9. FOCUS ON SELECT PLAYERS

Abbott Laboratories (US)
Abbott Molecular, Inc. (US)
Becton, Dickinson and Company (US)
bioMérieux SA (France)
Cepheid (US)
CytoCore Inc. (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
GE Healthcare (US)
Grifols International, S.A. (Spain)
Hologic, Inc. (US)
Hologic Gen-Probe Incorporated (US)
QIAGEN N.V. (The Netherlands)
Quest Diagnostics, Inc. (US)
Celera Corp. (US)
Siemens AG (Germany)
Tecan Group Ltd. (Switzerland)
The ELITechGroup SAS (France)
Thermo Fisher Scientific (US)

10. GLOBAL MARKET PERSPECTIVE

Table 29: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 30: World Historic Review for Molecular Diagnostics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 31: World 15-Year Perspective for Molecular Diagnostics by Geographic Region
Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Molecular Diagnostics Market by Application
Table 32: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Infectious Disease Testing by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 33: World Historic Review for Molecular Diagnostics in Infectious Disease Testing by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 34: World 15-Year Perspective for Molecular Diagnostics in Infectious Disease Testing by Geographic Region
Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 35: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Blood Screening by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 36: World Historic Review for Molecular Diagnostics in Blood Screening by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 37: World 15-Year Perspective for Molecular Diagnostics in Blood Screening by Geographic Region
Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 38: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Cancer Screening by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 39: World Historic Review for Molecular Diagnostics in Cancer Screening by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 40: World 15-Year Perspective for Molecular Diagnostics in Cancer Screening by Geographic Region
Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 41: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Other Applications by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 42: World Historic Review for Molecular Diagnostics in Other Applications by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 43: World 15-Year Perspective for Molecular Diagnostics in Other Applications by Geographic Region
Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A.Market Analysis
Molecular Diagnostics Maintain its Positive Momentum
A Glance at Major Growth Drivers
Key Challenges Facing the MDx Market
qPCR and dPCR Instrumentation in the US: An Overview
Ageing Demographics: Major Driving Factor
Table 44: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
Table 45: US Population Breakdown by Age Group: 2012 (includes corresponding Graph/Chart)
Increasing Burden of Chronic Diseases Drives Focus onto Molecular Diagnostics
US Individualized Medicine Market to Witness Significant Growth
Companion Diagnostic Market in the US
List of Select FDA-Cleared Companion Diagnostics
Number of Companion Diagnostics under Development Keeps Soaring
Burgeoning Potential for Genetic Testing
Direct-to-Consumer Testing
A Growing Market
Epidemic Proportion of Cancer in the US
Key Driver for Cancer Genetic Testing
Table 46: New Cancer Cases by Gender and Affected Site in the US (2013)
Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
List of FDA-Cleared CF MDx Tests
Table 47: CF Carrier Screening in the US (2012): Percentage Breakdown of Population by Coverage Policy (includes corresponding Graph/Chart)
Table 48: CF Diagnostic Testing in the US (2012): Percentage Breakdown of Population by Coverage Policy (includes corresponding Graph/Chart)
Molecular Diagnostics Tests Gaining Share in STD Testing Domain
HPV Testing Market
A Review
Table 49: Cervical Cancer by HPV Type in the US (2012): Percentage Share Breakdown of Cervical Cancer Cases by HPV Type (includes corresponding Graph/Chart)
Competitive Landscape
Table 50: Leading Players in the US HPV Testing Market (2010 & 2011): Percentage Share Breakdown of Number of Tests for QIAGEN, Hologic, and Roche (includes corresponding Graph/Chart)
List of FDA Approved HPV MDx Tests
Regulatory Environment
FDA Regulations
Clinical Laboratory Improvement Amendments (CLIA)
Table 51: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Laboratories by Certificate Type (includes corresponding Graph/Chart)
Table 52: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Labs by Lab Type (includes corresponding Graph/Chart)
Genetic Testing
FDA to Implement Strict Measures for Cervical Cancer Screening Tests
Limited Reimbursements
A Major Hindrance
New MoPath Codes for Reimbursement for Molecular Diagnostics Tests
Product Launches/Approvals
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 53: US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 54: US Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 55: US 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

2. CANADA

A.Market Analysis
Current and Future Analysis
A Statistical Review of Cancer Incidence in Canada
Table 56: New Cancer Cases in Canada by Gender and Affected Site: 2012 (includes corresponding Graph/Chart)
Table 57: New Cancer Cases in Canada by Province: 2012 (includes corresponding Graph/Chart)
Product Approval
B.Market Analytics
Table 58: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 59: Canadian Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 60: Canadian 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

3. JAPAN

A.Market Analysis
Current and Future Analysis
Demographics Drive Market Growth
Table 61: Percentage Breakdown of Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)
Table 62: Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart)
B.Market Analytics
Table 63: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 64: Japanese Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 65: Japanese 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4. EUROPE

A.Market Analysis
Current and Future Analysis
Debt Crisis in Europe Affects Healthcare Industry
European Healthcare System: In a State of Transition?
Insight into Molecular Diagnostics Markets in Europe
Table 66: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart)
Increasing Testing Needs of the Elderly: Business Case for Molecular Diagnostics
Table 67: Population Breakup by Age Group for Select European Countries: 2012 (As a % of Total Population) (includes corresponding Graph/Chart)
PCR Reagents in Europe: An Overview
Automated Systems Gain Preeminence
Oncology-based Molecular Diagnostics Holds Immense Potential
European Personalized Medicine Market to Exhibit Robust Growth
HPV Testing in Europe: An Overview
List of Select CE-Marked HPV Molecular Diagnostic Tests
Table 68: Cervical Cancer Incidence and Mortality in European Countries (2012)
Table 69: Prevalence of Cervical Cancer in European Countries (2012)
Table 70: European HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart)
Regulatory Scenario in Europe for Companion Diagnostics
Select European Players with Strong Biomarker Pipeline in Companion Diagnostics
Product Approvals/Launches
B.Market Analytics
Table 71: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 72: European Historic Review for Molecular Diagnostics by Geographic Region
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 73: European 15-Year Perspective for Molecular Diagnostics by Geographic Region
Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 74: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 75: European Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 76: European 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4a. FRANCE
A.Market Analysis
Current and Future Analysis
Product Launch
Strategic Corporate Development
Key Players
B.Market Analytics
Table 77: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 78: French Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 79: French 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4b. GERMANY
A.Market Analysis
Current and Future Analysis
Overview
Strategic Corporate Developments
Siemens AG
A Key Player
B.Market Analytics
Table 80: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 81: German Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 82: German 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4c. ITALY
A.Market Analysis
Current and Future Analysis
Product Launches
Strategic Corporate Developments
B.Market Analytics
Table 83: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 84: Italian Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 85: Italian 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A.Market Analysis
Current and Future Analysis
SMIP for Pharmacogenomic Testing
Product Launches
Strategic Corporate Developments
B.Market Analytics
Table 86: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 87: The UK Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 88: The UK 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4e. SPAIN
A.Market Analysis
Current and Future Analysis
Spain
Poised to become a Reckoning Force in Personalized Medicines
Strategic Corporate Development
Grifols International, S.A.
A Key Player
B.Market Analytics
Table 89: Spanish Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 90: Spanish Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 91: Spanish 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4f. RUSSIA
Market Analysis
Table 92: Russian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 93: Russian Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 94: Russian 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
4g. REST OF EUROPE
A.Market Analysis
Current and Future Analysis
Product Launches/Approvals
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 95: Rest of European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 96: Rest of European Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 97: Rest of European 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A.Market Analysis
Current and Future Analysis
Healthcare Spending in Asia-Pacific: On the Rise
In-vitro Diagnostics Market: India & China Offer Significant Growth Opportunities
Table 98: China and India Leads Global Population (July 2013):Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Million) by Age Group (includes corresponding Graph/Chart)
Table 99: Age-wise Breakup of China and India’s Population Vis-à-vis Other Populous Countries Globally: As of July 2013 (includes corresponding Graph/Chart)
Molecular Diagnostics Testing Opens New World of Possibilities
Recent Advancements in Molecular Diagnostics Market: A Quick Review
Novel Genetic Testing Methods
Development of Personalized Healthcare Approaches
Molecular Painting for Genetic Diagnosis of Diseases
New Technique to Detect H1N1 Virus
Strategic Corporate Development
B.Market Analytics
Table 100: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region
China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 101: Asia-Pacific Historic Review for Molecular Diagnostics by Geographic Region
China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 102: Asia-Pacific 15-Year Perspective for Molecular Diagnostics by Geographic Region
Percentage Breakdown of Revenues for China and Rest of Asia-Pacific Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Table 103: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 104: Asia-Pacific Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 105: Asia-Pacific 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
5a. CHINA
A.Market Analysis
Current and Future Analysis
In-Vitro Diagnostics Market on the Growth Curve
HPV Testing in China: An Overview
Government Support Drives Personalized Medicine Market in China
Product Launches
Strategic Corporate Developments
B.Market Analytics
Table 106: Chinese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 107: Chinese Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 108: Chinese 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
5b. REST OF ASIA-PACIFIC
A.Market Analysis
Current and Future Analysis
A Focus on the Indian Molecular Diagnostics Market
Molecular Diagnostic Market in India to Witness Significant Growth
Growth Drivers in a Nut Shell
Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
Indian Scientific Research towards Functional Genomics and Proteomics
Automation
The Emerging Trend in IVD Industry
Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
HPV Testing Market: An Overview
Table 109: HPV in India
Breakdown of Type-Distribution and HPV Prevalence (includes corresponding Graph/Chart)
Product Launches/Approvals
B.Market Analytics
Table 110: Rest of Asia Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 111: Rest of Asia Pacific Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 112: Rest of Asia Pacific 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

A.Market Analysis
Current and Future Analysis
Brazilian IVD Market on the Rise
B.Market Analytics
Table 113: Latin American Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 114: Latin American Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 115: Latin American 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

A.Market Analysis
Current and Future Analysis
Product Launch
B.Market Analytics
Table 116: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 117: Rest of World Historic Review for Molecular Diagnostics by Application
Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 118: Rest of World 15-Year Perspective for Molecular Diagnostics by Application
Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 165 (including Divisions/Subsidiaries 179)
The United States (113)
Canada (3)
Japan (1)
Europe (50)
France (7)
Germany (11)
The United Kingdom (12)
Italy (2)
Spain (1)
Rest of Europe (17)
Asia-Pacific (Excluding Japan) (11)
Middle East (1)
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/338507

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Oct 21th 2014
9:45:18 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Molecular Diagnostics - Global Strategic Business Report

Web Address

http://www.researchandmarkets.com/reports/338507

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 4,950
Electronic (PDF) - 1 - 5 Users USD 6,930
Electronic (PDF) - 1 - 10 Users USD 9,405
Electronic (PDF) - 1 - 15 Users USD 11,880

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Oct 21th 2014
9:45:18 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)